HYDROMORPHONE 8 MG
HYDROMORPHONE HYDROCHLORIDE : 8 MG · DIN 02192144 · SORRES PHARMA INC
Health Canada status: CANCELLED POST MARKET
What is HYDROMORPHONE?
HYDROMORPHONE 8 MG contains HYDROMORPHONE HYDROCHLORIDE : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02192144, held by SORRES PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 20-Jun-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HYDROMORPHONE used for?
HYDROmorphone (HYDROmorphone hydrochloride) is indicated for relief of moderate to severe pain.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02192144 |
|---|---|
| Brand name | HYDROMORPHONE |
| Generic / active ingredient | HYDROMORPHONE HYDROCHLORIDE : 8 MG |
| Manufacturer | SORRES PHARMA INC |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA03 HYDROMORPHONE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 20-Jun-2014 |
| Original market date | 2004-04-06 00:00:00 |
How is it administered?
Orally, for adults, 2 to 4 mg every 4 to 6 hours as required. Dose should be adjusted so that 3-4 hours of pain relief may be achieved.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
The tablets should be stored at 15-30 °C. Protect from light.
How is it supplied?
Bottles of 100 and Control Packs of 4 x 25.
Contraindications
Known hypersensitivity to the drug; respiratory depression in the absence of resuscitative equipment; status asthmaticus.
Warnings and precautions
Potential for drug dependence and abuse. Risk of severe respiratory depression, especially in elderly/debilitated. May increase intracranial pressure. May cause severe hypotension.
Is HYDROMORPHONE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AA03 HYDROMORPHONE. 34 of 85 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROMORPHONE | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02364115 |
| APO-HYDROMORPHONE | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02364123 |
| APO-HYDROMORPHONE | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02364131 |
| APO-HYDROMORPHONE | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02364158 |
| DILAUDID | 1 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00705438 |
| DILAUDID | 2 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125083 |
| DILAUDID | 4 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125121 |
| DILAUDID | 8 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00786543 |
| HYDROMORPH CONTIN | 4.5 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359502 |
| HYDROMORPH CONTIN | 9 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359510 |
Who else supplies HYDROMORPHONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROMORPHONE appears in 134 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.